DO-BO

What does environmental sustainability mean for Market Access, Gerdi Strydom?

Join us on the latest episode of MAP – the Market Access Podcast – where our host Dr. Stefan Walzer, together with special guest Gerdi Strydom, Managing Director at Valid Insight, explore the integration of ESG (Environmental, Social, and Governance) into Health Technology Assessments (HTAs).

In this episode, they unpack how healthcare’s carbon footprint and environmental impact are influencing policy, payor decisions, and industry strategies. Discover how leaders are addressing these challenges, the steps being taken in regions like the Nordics and the UK, and what the future holds for low-carbon pharmaceuticals.

This episode is for anyone who wants to get a better understanding of the growing role of environmental factors in HTAs as well as how global collaboration can drive sustainability in healthcare. Stay ahead of the trends in market access, and join the conversation around sustainability’s role in healthcare. Tune in now!

Related

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]